Biopharma Stock Skyrockets on FDA Approval

Today's news helped the stock break above a key trendline

Deputy Editor
Oct 12, 2021 at 10:26 AM
facebook twitter linkedin


Biopharmaceutical stock Protara Therapeutics Inc (NASDAQ:TARA) is surging today, up 11.9% to trade at $7.55 at last check. The U.S. Food and Drug Administration (FDA) approved the company's Investigational New Drug (IND) application for its non-muscle invasive bladder cancer treatment, TARA-002, with phase 1 cinical trials expected to begin by the end of the year. 

Protara Therapeutics stock has had a rough year on the charts. Down 68.9% year-to-date, the shares hit an Oct. 6, record low of $6.18. However, today's pop has the equity breaking above the 60-day moving average, which had been guiding TARA lower since late February. 

The security's typically quiet options pits are bursting with activity this morning. Options volume is running at 280 times the intraday average, and pacing for the top percentile of its annual range. So far, 2,902 calls and 184 puts have crossed the tape. The November 10 call is the most popular, followed by the October 10 call, with new positions being opened at both. 

The brokerage bunch seems unlikely to chime in after the news, as there is hardly any room for bull notes. All four analysts in coverage carry a "strong buy" rating on TARA. Plus, the 12-month consensus price target of $40 is a 429.1% premium to current levels. 

 

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

 


 


 
Special Offers from Schaeffer's Trading Partners